Back to Search
Start Over
Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
- Source :
-
Clinical nuclear medicine [Clin Nucl Med] 2016 Nov; Vol. 41 (11), pp. 894-895. - Publication Year :
- 2016
-
Abstract
- An 81-year-old castrate-resistant prostate cancer man with multiple lymph node, bone, and hepatic metastases received four cycles of Lu-PSMA-617 treatments at our department from May to December 2015. All of his liver metastases showed PSMA expression in Ga-PSMA PET performed before the first cycle. Under this therapy, all of the metastases showed significant regression in size and PSMA expression over time.
- Subjects :
- Aged, 80 and over
Humans
Liver Neoplasms diagnostic imaging
Liver Neoplasms secondary
Lutetium
Male
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant diagnostic imaging
Prostatic Neoplasms, Castration-Resistant pathology
Dipeptides therapeutic use
Heterocyclic Compounds, 1-Ring therapeutic use
Liver Neoplasms radiotherapy
Prostatic Neoplasms, Castration-Resistant radiotherapy
Radiopharmaceuticals therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1536-0229
- Volume :
- 41
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Clinical nuclear medicine
- Publication Type :
- Academic Journal
- Accession number :
- 27607162
- Full Text :
- https://doi.org/10.1097/RLU.0000000000001358